Establishment Labs appoints Taylor Harris to Board of Directors

ESTABLISHMENT LABS HOLDINGS INC.

Taylor Harris appointed to Board effective June 24, 2026; will serve on Audit and Nominating & Governance Committees.
25+ years experience in healthcare, medtech, and life sciences; most recently CEO of Cutera and CFO of MyoKardia (acquired by BMS for $13.1B).
New director receives initial equity grant of $170,000 under updated non-employee director compensation policy.
Harris's appointment fills a board seat until the 2027 annual meeting; no arrangements or material interests with other parties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.